Sputum biomarkers of inflammation in cystic fibrosis lung disease

Proceedings of the American Thoracic Society

Volumn 4, Issue 4, 2007, Pages 406-417

  Sagel, Scott D ^a,c   Chmiel, James F ^b   Konstan, Michael W ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CHILDREN S HOSPITAL   (United States)

Author keywords

Biomarkers; Cystic fibrosis; Inflammation; Lung disease; Sputum

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARACHIDONIC ACID; AZITHROMYCIN; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DESMOSINE; DORNASE ALFA; ELASTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; LEUKOTRIENE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; RANTES; RETINOID X RECEPTOR ALPHA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DIAGNOSTIC APPROACH ROUTE; DISEASE EXACERBATION; DISEASE SEVERITY; GENETIC TRANSCRIPTION; HUMAN; LONGITUDINAL STUDY; LUNG DISEASE; LUNG LAVAGE; MEASUREMENT; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTION; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFLAMMATION; SIGNAL TRANSDUCTION; SPUTUM ANALYSIS; TRACHEOBRONCHIAL TOILET; TREATMENT RESPONSE; VALIDITY;

BIOLOGICAL MARKERS; CLINICAL TRIALS; CYSTIC FIBROSIS; HUMANS; INFLAMMATION; LUNG DISEASES; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SPUTUM;

EID: 34548282581     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200703-044BR     Document Type: Conference Paper

References (171)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-1256.
2. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002;23:5-27.
3. Chmiel JF, Konstan MW. Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med 2005;4:255-273.
4. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995;126:515-523.
5. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
6. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999;115:1053-1058.
7. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, Farrell PM. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000;342:851-859.
8. Konstan MW, Davis PB. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev 2002;54:1409-1423.
9. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997;41:161-165.
10. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-377.
11. Sagel SD, Accurso FJ. Monitoring inflammation in CF: cytokines. Clin Rev Allergy Immunol 2002;23:41-57.
12. Courtney JM, Ennis M, Elborn JS. Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros 2004;3:223-231.
13. Bedrossian CW, Greenberg SD, Singer DB, Hansen JJ, Rosenberg HS. The lung in cystic fibrosis. a quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976;7:195-204.
14. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152:2111-2118.
15. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998;101:2598-2605.
16. Li J, Johnson XD, Iazvovskaia S, Tan A, Lin A, Hershenson MB. Signaling intermediates required for NF-kappa B activation and IL-8 expression in CF bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2003;284:L307-L315.
17. Barnes PJ. Transcription factors in airway diseases. Lab Invest 2006;86:867-872.
18. Kraynack NC, Corey DA, Elmer HL, Kelley TJ. Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002;283:L604-L611.
19. Bozinovski S, Jones JE, Vlahos R, Hamilton JA, Anderson GP. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J Biol Chem 2002;277:42808-42814.
20. Delgado MA, Poschet JF, Deretic V. Nonclassical pathway of Pseudomonas aeruginosa DNA-induced interleukin-8 secretion in cystic fibrosis airway epithelial cells. Infect Immun 2006;74:2975-2984.
21. Sadikot RT, Christman JW, Blackwell TS. Molecular targets for modulating lung inflammation and injury. Curr Drug Targets 2004;5:581-588.
22. Chmiel JF, Davis PB. Inflammatory responses in the cystic fibrosis lung. In: Kirk KL, Dawson DC, editors. The CFTR chloride channel, 1st ed. Georgetown, TX: Landes Bioscience; 2003. pp. 160-180.
23. Kube D, Sontich U, Fletcher D, Davis PB. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001;280:L493-L502.
24. Saba S, Soong G, Greenberg S, Prince A. Bacterial stimulation of epithelial G-CSF and GM-CSF expression promotes PMN survival in CF airways. Am J Respir Cell Mol Biol 2002;27:561-567.
25. Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007;292:L383-L395.
26. Ruef C, Jefferson DM, Schlegel-Haueter SE, Suter S. Regulation of cytokine secretion by cystic fibrosis airway epithelial cells. Eur Respir J 1993;6:1429-1436.
27. Jensen PO, Moser C, Kharazmi A, Presler T, Koch C, Hoiby N. Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia. J Cyst Fibros 2006;5:145-151.
28. Bedard M, McClure CD, Schiller NL, Francoeur C, Cantin A, Denis M. Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am J Respir Cell Mol Biol 1993;9:455-462.
29. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995;13:257-261.
30. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999;104:72-78.
31. Soltys J, Bonfield T, Chmiel J, Berger M. Functional IL-10 deficiency in the lung of cystic fibrosis (Cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J Immunol 2002;168:1903-1910.
32. Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (cf) peripheral lymphocytes. Clin Exp Immunol 2000;120:518-525.
33. Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, Gardner P. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol 1996;106:374-388.
34. Osika E, Cavaillon JM, Chadelat K, Boule M, Fitting C, Tournier G, Clement A. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J 1999;14:339-346.
35. Schwiebert LM, Estell K, Propst SM. Chemokine expression in CF epithelia: implications for the role of CFTR in RANTES expression. Am J Physiol 1999;276:C700-C710.
36. Kube DM, Fletcher D, Davis PB. Relation of exaggerated cytokine responses of CF airway epithelial cells to PAO1 adherence. Respir Res 2005;6:69.
37. McDonald TV, Nghiem PT, Gardner P, Martens CL. Human lymphocytes transcribe the cystic fibrosis transmembrane conductance regulator gene and exhibit CF-defective CAMP-regulated chloride current. J Biol Chem 1992;267:3242-3248.
38. Yoshimura K, Nakamura H, Trapnell BC, Chu CS, Dalemans W, Pavirani A, Lecocq JP, Crystal RG. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991;19:5417-5423.
39. Krauss RD, Berta G, Rado TA, Bubien JK. Antisense oligonucleotides to CFTR confer a cystic fibrosis phenotype on B lymphocytes. Am J Physiol 1992;263:C1147-C1151.
40. Hubeau C, Lorenzato M, Couetil JP, Hubert D, Dusser D, Puchelle E, Gaillard D. Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa. Clin Exp Immunol 2001;124:69-76.
41. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005;175:404-412.
42. Perez A, Risma KA, Eckman EA, Davis PB. Overexpression of R domain eliminates CAMP-stimulated Cl- secretion in 9/HTEo- cells in culture. Am J Physiol 1996;271:L85-L92.
43. Steagall WK, Elmer HL, Brady KG, Kelley TJ. Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression. Am J Respir Cell Mol Biol 2000;22:45-50.
44. Kelley TJ, Elmer HL. In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J Clin Invest 2000;106:403-410.
45. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
46. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997;24:137-142.
47. Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 1996;75:319-322.
48. Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997;24:173-177.
49. Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Lester KH, Berger M. Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med 2002;165:1176-1181.
50. Chmiel JF, Konstan MW, Knesebeck JE, Hilliard JB, Bonfield TL, Dawson DV, Berger M. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med 1999;160:2040-2047.
51. Ollero M, Junaidi O, Zaman MM, Tzameli I, Ferrando AA, Andersson C, Blanco PG, Bialecki E, Freedman SD. Decreased expression of peroxisome proliferator activated receptor gamma in Cftr-/- mice. J Cell Physiol 2004;200:235-244.
52. Green S. PPAR: a mediator of peroxisome proliferator action. Mutat Res 1995;333:101-109.
53. Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G. A paradigm for gene regulation: inflammation, NFkappaB and PPAR. Adv Exp Med Biol 2003;544:181-196.
54. Davis PB, Gupta S, Eastman J, Konstan MW. Inhibition of proinflammatory cytokine production by PPARgamma agonists in airway epithelial cells [abstract]. Pediatr Pulmonol Suppl 2003;25:A246.
55. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993;148:896-901.
56. Meyer KC, Zimmerman J. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 1993;121:654-661.
57. Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207-213.
58. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454.
59. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571-1572.
60. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997;175:638-647.
61. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-191.
62. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001;32:356-366.
63. Meyer KC, Lewandoski JR, Zimmerman JJ, Nunley D, Calhoun WJ, Dopico GA. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis: comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. Am Rev Respir Dis 1991;144:580-585.
64. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392-394.
65. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG. Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90:1296-1301.
66. Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group. J Pediatr 1998;133:486-491.
67. Roum JH, Borok Z, McElvaney NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 1999;87:438-443.
68. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoy KS, Shell R, Borowitz D, Konstan MW, Retsch-Bogart G, Wilmott RW, et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001;139:572-577.
69. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849.
70. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, Van Koningsbruggen S, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-725.
71. Ratjen F, Paul K, Van Koningsbruggen S, Breitenstein S, Rietschel E, Nikolaizik W. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 2005;39:1-4.
72. Hilliard JB, Konstan MW, Davis PB. Inflammatory mediators in CF patients. In: Skach WR, editor. Cystic fibrosis methods and protocols. Totowa, NJ: Humana Press; 2002. pp. 409-432.
73. Davis SD, Brody AS, Emond MJ, Brumback LC, Rosenfeld M. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc 2007;4:418-430.
74. Cunningham S, McColm JR, Ho LP, Greening AP, Marshall TG. Measurement of inflammatory markers in the breath condensate of children with cystic fibrosis. Eur Respir J 2000;15:955-957.
75. Carpagnano GE, Barnes PJ, Geddes DM, Hodson ME, Kharitonov SA. Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am J Respir Crit Care Med 2003;167:1109-1112.
76. Carpagnano GE, Barnes PJ, Francis J, Wilson N, Bush A, Kharitonov SA. Breath condensate pH in children with cystic fibrosis and asthma: a new noninvasive marker of airway inflammation? Chest 2004;125:2005-2010.
77. Bodini A, D'Orazio C, Peroni D, Corradi M, Folesani G, Baraldi E, Assael BM, Boner A, Piacentini GL. Biomarkers of neutrophilic inflammation in exhaled air of cystic fibrosis children with bacterial airway infections. Pediatr Pulmonol 2005;40:494-499.
78. Robroeks CM, Jobsis Q, Damoiseaux JG, Heijmans PH, Rosias PP, Hendriks HJ, Dompeling E. Cytokines in exhaled breath condensate of children with asthma and cystic fibrosis. Ann Allergy Asthma Immunol 2006;96:349-355.
79. Celio S, Troxler H, Durka SS, Chladek J, Wildhaber JH, Sennhauser FH, Heizmann CW, Moeller A. Free 3-nitrotyrosine in exhaled breath condensates of children fails as a marker for oxidative stress in stable cystic fibrosis and asthma. Nitric Oxide 2006;15:226-232.
80. Rosias PP, Den Hartog GJ, Robroeks CM, Bast A, Donckerwolcke RA, Heynens JW, Suykerbuyk J, Hendriks HJ, Jobsis Q, Dompeling E. Free radicals in exhaled breath condensate in cystic fibrosis and healthy subjects. Free Radic Res 2006;40:901-909.
81. Johansen HK, Norregaard L, Gotzsche PC, Pressler T, Koch C, Hoiby N. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success? A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol 2004;37:427-432.
82. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, Collins J, Rock MJ, Splaingard ML. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-588.
83. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Doring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007;42:249-255.
84. Dorlochter L, Carlsson M, Olafsdottir EJ, Roksund OD, Rosendahl K, Fluge G. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. J Cyst Fibros 2004;3:179-183.
85. Downey DG, Martin SL, Dempster M, Moore JE, Keogan MT, Starcher B, Edgar J, Bilton D, Elborn JS. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol 2007;42:216-220.
86. Levy H, Kalish LA, Huntington I, Weller N, Gerard C, Silverman EK, Celedon JC, Pier GB, Weiss ST. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol 2007;42:256-262.
87. Brown MA, Morgan WJ, Finley PR, Scuderi P. Circulating levels of tumor necrosis factor and interleukin-1 in cystic fibrosis. Pediatr Pulmonol 1991;10:86-91.
88. Norman D, Elborn JS, Cordon SM, Rayner RJ, Wiseman MS, Hiller EJ, Shale DJ. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax 1991;46:91-95.
89. Dean TP, Dai Y, Shute JK, Church MK, Warner JO. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res 1993;34:159-161.
90. Greally P, Hussain MJ, Vergani D, Price JF. Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis. Arch Dis Child 1993;68:785-787.
91. Kronborg G, Hansen MB, Svenson M, Fomsgaard A, Hoiby N, Bendtzen K. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol 1993;15:292-297.
92. Wilmott RW, Frenzke M, Kociela V, Peng L. Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol 1994;18:21-27.
93. McColley SA, Stellmach V, Boas SR, Jain M, Crawford SE. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 2000;161:1877-1880.
94. Augarten A, Paret G, Avneri I, Akons H, Aviram M, Bentur L, Blau H, Efrati O, Szeinberg A, Barak A, et al. Systemic inflammatory mediators and cystic fibrosis genotype. Clin Exp Med 2004;4:99-102.
95. Schmitt-Grohe S, Naujoks C, Bargon J, Wagner TO, Schubert R, Hippe V, Zielen S. Interleukin-8 in whole blood and clinical status in cystic fibrosis. Cytokine 2005;29:18-23.
96. Moser C, Jensen PO, Pressler T, Frederiksen B, Lanng S, Kharazmi A, Koch C, Hoiby N. Serum concentrations of GM-CSF and G-CSF correlate with the Th1/Th2 cytokine response in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. APMIS 2005;113:400-409.
97. Ionescu AA, Mickleborough TD, Bolton CE, Lindley MR, Nixon LS, Dunseath G, Luzio S, Owens DR, Shale DJ. The systemic inflammatory response to exercise in adults with cystic fibrosis. J Cyst Fibros 2006;5:105-112.
98. Elborn JS, Norman D, Delamere FM, Shale DJ. In vitro tumor necrosis factor-α secretion by monocytes from patients with cystic fibrosis. Am J Respir Cell Mol Biol 1992;6:207-211.
99. Hauber HP, Gholami D, Koppermann G, Heuer HE, Meyer A, Pforte A. Increased expression of interleukin-13 but not interleukin-4 in cystic fibrosis patients. J Cyst Fibros 2003;2:189-194.
100. Corvol H, Fitting C, Chadelat K, Jacquot J, Tabary O, Boule M, Cavaillon JM, Clement A. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2003;284:L997-1003.
101. Hauber HP, Beyer IS, Meyer A, Pforte A. Decreased interleukin-18 expression in BAL cells and peripheral blood mononuclear cells in adult cystic fibrosis patients. J Cyst Fibros 2004;3:129-131.
102. Zaman MM, Gelrud A, Junaidi O, Regan MM, Warny M, Shea JC, Kelly C, O'Sullivan BP, Freedman SD. Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaf508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol 2004;11:819-824.
103. Brazova J, Sediva A, Pospisilova D, Vavrova V, Pohunek P, Macek M Jr, Bartunkova J, Lauschmann H. Differential cytokine profile in children with cystic fibrosis. Clin Immunol 2005;115:210-215.
104. Rayner RJ, Wiseman MS, Cordon SM, Norman D, Hiller EJ, Shale DJ. Inflammatory markers in cystic fibrosis. Respir Med 1991;85:139-145.
105. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998;157:1764-1769.
106. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995;152:157-162.
107. Sampson AP, Spencer DA, Green CP, Piper PJ, Price JF. Leukotrienes in the sputum and urine of cystic fibrosis children. Br J Clin Pharmacol 1990;30:861-869.
108. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF Jr, Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985;132:529-535.
109. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112:547-554.
110. Richman-Eisenstat JB, Jorens PG, Hebert CA, Ueki I, Nadel JA. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993;264:L413-L418.
111. Greally P, Hussein MJ, Cook AJ, Sampson AP, Piper PJ, Price JF. Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993;68:389-392.
112. Regelmann WE, Siefferman CM, Herron JM, Elliott GR, Clawson CC, Gray BH. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatr Pulmonol 1995;19:1-9.
113. Koller DY, Nething I, Otto J, Urbanek R, Eichler I. Cytokine concentrations in sputum from patients with cystic fibrosis and their relation to eosinophil activity. Am J Respir Crit Care Med 1997;155:1050-1054.
114. Wolter JM, Rodwell RL, Bowler SD, McCormack JG. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Clin Diagn Lab Immunol 1999;6:260-265.
115. Pukhalsky AL, Kapranov NI, Kalashnikova EA, Shmarina GV, Shabalova LA, Kokarovtseva SN, Pukhalskaya DA, Kashirskaja NJ, Simonova OI. Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection. Mediators Inflamm 1999;8:159-167.
116. Karpati F, Hjelte FL, Wretlind B. TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis 2000;32:75-79.
117. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001;164:1425-1431.
118. Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168:1471-1475.
119. Thomassen MJ, Klinger JD, Badger SJ, van Heeckeren DW, Stern RC. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr 1984;104:352-356.
120. Gilljam H, Malmborg AS, Strandvik B. Conformity of bacterial growth in sputum and contamination free endobronchial samples in patients with cystic fibrosis. Thorax 1986;41:641-646.
121. Aaron SD, Kottachchi D, Ferris WJ, Vandemheen KL, St Denis ML, Plouffe A, Doucette SP, Saginur R, Chan FT, Ramotar K. Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J 2004;24:631-637.
122. van Belkum A, Renders NH, Smith S, Overbeek SE, Verbrugh HA. Comparison of conventional and molecular methods for the detection of bacterial pathogens in sputum samples from cystic fibrosis patients. FEMS Immunol Med Microbiol 2000;27:51-57.
123. Kolak M, Karpati F, Monstein HJ, Jonasson J. Molecular typing of the bacterial flora in sputum of cystic fibrosis patients. Int J Med Microbiol 2003;293:309-317.
124. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2003;41:3548-3558.
125. Pedersen SK, Sloane AJ, Prasad SS, Sebastian LT, Lindner RA, Hsu M, Robinson M, Bye PT, Weinberger RP, Harry JL. An immunoproteomic approach for identification of clinical biomarkers for monitoring disease: application to cystic fibrosis. Mol Cell Proteomics 2005;4:1052-1060.
126. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr 2002;141:811-817.
127. Dakin CJ, Pereira JK, Henry RL, Wang H, Morton JR. Relationship between sputum inflammatory markers, lung function, and lung pathology on high-resolution computed tomography in children with cystic fibrosis. Pediatr Pulmonol 2002;33:475-482.
128. Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005;39:224-232.
129. Kim JS, Okamoto K, Rubin BK. Pulmonary function is negatively correlated with sputum inflammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis. Chest 2006;129:1148-1154.
130. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175:822-828.
131. Salva PS, Doyle NA, Graham L, Eigen H, Doerschuk CM. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol 1996;21:11-19.
132. Schuster A, Haarmann A, Wahn V. Cytokines in neutrophil-dominated airway inflammation in patients with cystic fibrosis. Eur Arch Otorhinolaryngol 1995;252:S59-S60.
133. Francoeur C, Denis M. Nitric oxide and interleukin-8 as inflammatory components of cystic fibrosis. Inflammation 1995;19:587-598.
134. Cunningham S, McColm JR, Mallinson A, Boyd I, Marshall TG. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis. Pediatr Pulmonol 2003;36:43-48.
135. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007;19:83-88.
136. Shah PL, Scott SF, Knight RA, Hodson ME. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996;9:531-534.
137. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
138. Reinhardt N, Chen CI, Loppow D, Schink T, Kleinau I, Jorres RA, Wahn U, Magnussen H, Paul KP. Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison With BAL. Eur Respir J 2003;22:497-502.
139. Smountas AA, Lands LC, Mohammed SR, Grey V. Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers. Clin Biochem 2004;37:1031-1036.
140. Ordonez CL, Kartashov AI, Wohl ME. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis. J Pediatr 2004;145:689-692.
141. Meyer KC, Sharma A. Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 1997;156:1536-1540.
142. Efthimiadis A, Pizzichini MM, Pizzichini E, Dolovich J, Hargreave FE. Induced sputum cell and fluid-phase indices of inflammation: comparison of treatment with dithiothreitol vs phosphate-buffered saline. Eur Respir J 1997;10:1336-1340.
143. Louis R, Shute J, Goldring K, Perks B, Lau LC, Radermecker M, Djukanovic R. The effect of processing on inflammatory markers in induced sputum. Eur Respir J 1999;13:660-667.
144. Grebski E, Peterson C, Medici TC. Effect of physical and chemical methods of homogenization on inflammatory mediators in sputum of asthma patients. Chest 2001;119:1521-1525.
145. Kim JS, Hackley GH, Okamoto K, Rubin BK. Sputum processing for evaluation of inflammatory mediators. Pediatr Pulmonol 2001;32:152-158.
146. Woolhouse IS, Bayley DL, Stockley RA. Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax 2002;57:667-671.
147. Kelly MM, Keatings V, Leigh R, Peterson C, Shute J, Venge P, Djukanovic R. Analysis of fluid-phase mediators. Eur Respir J Suppl 2002;37:24s-39s.
148. Hilliard J, Minillo B, Krenicky J, Pallotta S, Konstan M. Sputum in cystic fibrosis: preliminary evaluation of in vitro digestive methods using representative outcome measures [abstract]. Pediatr Pulmonol Suppl 2004;27:271.
149. Gibson PG, Girgis-Gabardo A, Morris MM, Mattoli S, Kay JM, Dolovich J, Denburg J, Hargreave FE. Cellular characteristics of sputum from patients with asthma and chronic bronchitis. Thorax 1989;44:693-699.
150. Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, Dolovich J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25-29.
151. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993;147:1126-1131.
152. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;95:843-852.
153. Henry RL, Gibson PG, Carty K, Cai Y, Francis JL. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis. Pediatr Pulmonol 1998;26:97-100.
154. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002;166:352-355.
155. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-984.
156. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125:509-521.
157. Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, et al. Randomized,
158. Husson MO, Wizla-Derambure N, Turck D, Gosset P, Wallaert B. Effect of intermittent inhaled tobramycin on sputum cytokine profiles in cystic fibrosis. J Antimicrob Chemother 2005;56:247-249.
159. Colombo C, Costantini D, Rocchi A, Cariani L, Garlaschi ML, Tirelli S, Calori G, Copreni E, Conese M. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 2005;40:15-21.
160. Stelmach I, Korzeniewska A, Stelmach W, Majak P, Grzelewski T, Jerzynska J. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Ann Allergy Asthma Immunol 2005;95:372-380.
161. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006;41:177-183.
162. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006;103:4628-4633.
163. Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, Davis PB, Hoppel CL. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003;306:1086-1091.
164. Suri R, Marshall LJ, Wallis C, Metcalfe C, Shute JK, Bush A. Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol 2003;35:309-313.
165. Nightingale JA, Rogers DF, Barnes PJ. Effect of repeated sputum induction on cell counts in normal volunteers. Thorax 1998;53:87-90.
166. Holz O, Richter K, Jorres RA, Speckin P, Mucke M, Magnussen H. Changes in sputum composition between two inductions performed on consecutive days. Thorax 1998;53:83-86.
167. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanovic R, Maestrelli P, Sterk PJ. Sputum induction. Eur Respir J Suppl 2002;37:3s-8s.
168. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, Pizzichini MM, Pizzichini E, Ronchi C, Van Overvel F, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002;37:19s-23s.
169. Tirelli AS, Colombo C, Torresani E, Cariani L, Arnaboldi E, Conese M. Validation of an automated sensitive immunoassay for quantitation of cytokines in the sputum of cystic fibrosis patients. Clin Chem Lab Med 2007;45:108-111.
170. Cummings DM, King DE, Mainous AG, Geesey ME. Combining serum biomarkers: the association of C-reactive protein, insulin sensitivity, and homocysteine with cardiovascular disease history in the general US population. Eur J Cardiovasc Prev Rehabil 2006;13:180-185.
171. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-1763.